Table 1.
Eligibility criteria for patients of metastatic castration resistant prostate cancer in this study
| Patients eligible for 225Ac-PSMA-617 therapy |
| Histopathologically confirmed adenocarcinoma prostate |
| Documented castration resistant prostate cancer with distant metastatic disease |
| Progressive disease despite ≥2 prior treatment options |
| Tracer avid lesion (s) on 68Ga-PSMA-11 PET/CT (SUVmax of lesion being at least 1.5 times greater than that of normal liver) |
| Stable haematological parameters: Haemoglobin ≥9 g/dL; Total leucocyte count ≥3000/mcL; Neutrophils ≥1500/mcL; Platelets ≥75,000/mcL |
| GFR ≥30 mL/min |
| Serum albumin ≥2.5 g/dL |
| ECOG performance 0-2 |
| Patients ineligible for 225Ac-PSMA-617 therapy |
| Sarcomatous/spindle cell/small cell differentiation on histology |
| Nontracer avid lesions or tracer avidity less than that of liver |
| Second malignancies |
| Patients on concurrent anti-tumour medications |
GFR: Glomerular filtration rate; SUVmax: Standardized Uptake Value – maximum, ECOG: Eastern Cooperation of Oncology Group, PSMA: Prostate Specific Membrane Antigen, 225Ac: Actinium-225, PET-CT: Positron emission tomography - computed tomography